Clinical trial
Tysabri Observational Program
NCT00493298 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00493298 |
|---|---|
| Title | Tysabri Observational Program |
| Official title | TOP: TYSABRI Observational Program |
| Acronym | TOP |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Tysabri |
| Enrollment | 6,620 |
| Start date | Jun 29, 2007 |
| Primary completion | Nov 1, 2023 |
| Completion | Nov 1, 2023 |
| First posted | Jun 28, 2007 |
| Last update posted | Apr 8, 2024 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Czechia, Finland, France, Germany, Greece, Italy, Mexico and 6 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: